International Journal of Research and Development in Pharmacy & Life Sciences <p><img src="" alt="" width="400" height="207" /></p> <ol> <li><strong>Journal Title: </strong>International Journal of Research and Development in Pharmacy &amp; Life Sciences (IJRDPL)</li> <li><strong>Discipline, Focus &amp; Scope: </strong>Pharmaceutical Sciences, Medical Sciences &amp; Life Sciences</li> <li><strong>Publisher: </strong>Society for research and Development in Education</li> <li><strong>Country: </strong>India</li> <li><strong>Language: </strong>English</li> <li><strong>Publishing Frequency: </strong>Bi-monthly</li> <li><strong>Current Status:</strong>Online &amp; Print</li> <li><strong>e-ISSN: </strong>2278-0238<strong>P-ISSN:</strong> 2393-932X</li> <li><strong>Membership</strong>: International Committee of Medical Journal Editors (<a href="">ICMJE</a>)</li> <li><strong>Year of Start</strong>: 2012</li> <li><strong>CODEN (CAS-USA):</strong><strong><a href="">IJRDA9</a></strong></li> </ol> <p style="text-align: justify; font-size: 16px;"><strong>Email:</strong></p> <p style="text-align: justify; font-size: 16px;"><strong>Website:</strong> <a href=""></a></p> <p style="text-align: justify; font-size: 16px;">International Journal of Research and Development in Pharmacy &amp; Life Sciences (IJRDPL) is an official publication of SRDE (Society for research and Development in Education). It is an international peer-reviewed, open access, multidisciplinary journal, scheduled to appear bi-monthly and with the aim to serve as a mean for scientific information exchange and understandings at international pharmaceutical and life sciences forum.</p> <p style="text-align: justify; font-size: 16px;">International Journal of Research and Development in Pharmacy &amp; Life Sciences (IJRDPL) publishes original research articles; review articles; short communications; case reports; letters to the editors and rapid communications in all areas of Pharmaceutical and Basic Life Sciences.</p> <p style="text-align: justify; font-size: 16px;">“We support HIFA (Healthcare Information for All). We believe that every person and every health worker should have access to the health information they need to protect their own health and the health of others. We encourage you to join HIFA here: <a href="" target="_blank" rel="noopener"></a>“</p> <p><sup><img src="" alt="" width="111" height="114" /></sup></p> en-US (Managing Editor) (Ubitech Solutions Pvt Ltd) Tue, 22 Sep 2020 15:22:09 +0000 OJS 60 Preliminary phytochemical screening of bark (powder) extracts of Ficus religiosa (peepal) plant <p>The traditional medicine involves the use of various different plant extracts&nbsp; or&nbsp; the&nbsp; bioactive&nbsp; constituents.&nbsp; The&nbsp; study&nbsp; such&nbsp; as&nbsp; ethno&nbsp; medicine&nbsp; keenly&nbsp;&nbsp; r presents the best avenues in searching new economic plants for medicine. This type&nbsp; of study gives the health application at affordable cost. The present study carried out to find out the phytochemical constituents in the <em>Ficus religiosa </em>bark. The <em>Ficus religiosa </em>was collected from the Rama University Campus. The shadow dried bark materials were grained and extracted with petroleum ether, chloroform, methanol and ethanol: water (50: 50). Photochemical analysis was carried out according to standard procedures. The bark powder was successively extracted ith Phytochemical screening shows the presence of carbohydrate, glycoside, alk loid, protein, amino acid, phytosterol, tannin &amp; flavonoids. The result of the study could be useful for description and phytochemical analysis of the plant.</p> Priya Tiwari, Rishikesh Gupta Copyright (c) 2020 Mon, 15 Jun 2020 00:00:00 +0000 A prospective observational study on the effect of Erythropoiesis stimulating agents in chronic kidney disease Anemia patients <p><strong>Background and Objectives: </strong>Anemia is a frequent complication, and significant morbidity and mortality in patient with chronic kidney disease (CKD). Erythropoiesis Stimulating Agents (ESAs) have become the standard care for&nbsp; anemia&nbsp;&nbsp; t erapy and reduces need for blood transfusions. The bjective of the study was to evaluate the safety&nbsp; and&nbsp; effect&nbsp; of&nbsp; ESAs&nbsp; and&nbsp; to&nbsp; create&nbsp; the&nbsp; awareness&nbsp; among patients&nbsp;&nbsp;&nbsp; regarding&nbsp;&nbsp;&nbsp;&nbsp; the&nbsp;&nbsp;&nbsp;&nbsp; Erythropoiesis&nbsp;&nbsp;&nbsp;&nbsp; stimulating&nbsp;&nbsp;&nbsp; agents&nbsp;&nbsp;&nbsp;&nbsp; through&nbsp;&nbsp;&nbsp; patient i formation leaflets. <br><br><strong>Methods</strong>: The prospective observational study of&nbsp; 6-month duration was conducted in a tertiary care hospital. A total of 162 patients on ESAs&nbsp; were enrolled in the study. Patients were followed for continuously and the mean difference is assessed by monitoring the primary and secondary hematological parameters before and after ESAs administration. Patient information leaflet was given t the patients for education and awareness about ESAs. <br><br><strong>Results</strong>: Out of 162 patients, after the administration of ESAs mean value increase in hemoglobin level was found from base line 6.9g/dL to 11.6g/dL. Significant improvement was noted in CKD anemia patient indicating impact of patient counseli g. <br><br><strong>Conclusion</strong>: It can be&nbsp; concluded that Erythropoiesis Stimulating Agents in treatment of anemia along with effective counseling from clinical pharmacist benefits CKD patients and improves the health outcomes.</p> Manjumol Jose, Sonia Kumari Singh, Vinson Achankunju, Punitha Sundaraswamy, Sheik Haja Sherief , Sivakumar Thangaval Copyright (c) 2020 Mon, 15 Jun 2020 00:00:00 +0000